BioCryst receives additional NIAID funding to develop Marburg treatment
The funding will come from the National Institute of Allergy and Infectious Diseases, which exercised an option to conduct an investigational new drug enabling program and submit an investigational new drug application for BCX4430. BioCryst previously received an initial award of $5.0 million in September from the NIAID.
If all contract options are exercised, the total funding from NIAID could be as much as $22.0 million over five years and would advance the program through Phase I trials.
"With these additional funds, BioCryst will rapidly initiate IND-enabling studies of intramuscular BCX4430," William Sheridan, the chief medical officer at BioCryst, said. "This is an important next step in moving the development program forward to an IND submission, leading to an initial safety trial in healthy human volunteers."
The contract goals are to file IND applications for intramuscular and intravenous BCX4430 to treat Marburg virus disease and conduct Phase I human clinical trials.
BCX4430 is an RNA-dependent RNA polymerase inhibitor that previously demonstrated broad-spectrum activity for multiple viruses, in addition to a favorable preliminary preclinical safety profile. BioCryst is developing BCX4430 through the animal rule regulatory pathway.